Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer

Gynecologic Oncology

Volumn 125, Issue 3, 2012, Pages 625-630

  Laskey, Robin A ^b   Poniewierski, Marek S ^b   Lopez, Micael A ^a,b   Hanna, Rabbie K ^c   Secord, Angeles Alvarez ^a,b,d   Gehrig, Paola A ^c   Lyman, Gary H ^b,d   Havrilesky, Laura J ^a,b,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d DUKE CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Febrile neutropenia; Growth factor support; Ovarian cancer; Severe neutropenia

Indexed keywords

CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ABSOLUTE NEUTROPHIL COUNT; ADULT; ADVANCED CANCER; AGED; BODY MASS; BODY SURFACE; CANCER STAGING; CAUCASIAN; CLINICAL PROTOCOL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CANCER; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; RELATIVE DOSE INTENSITY; RETROSPECTIVE STUDY; RISK FACTOR; TEMPERATURE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84861182422     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.015     Document Type: Conference Paper

References (41)

1. M.S. Aapro, D.A. Cameron, R. Pettengell, J. Bohlius, J. Crawford, and M. Ellis EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2006 2433 2453
2. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
3. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
4. P.A. Vasey, G.C. Jayson, A. Gordon, H. Gabra, R. Coleman, and R. Atkinson Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 2004 1682 1691
5. N.M. Kuderer, D.C. Dale, J. Crawford, L.E. Cosler, and G.H. Lyman Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2006 2258 2266
6. V. Caggiano, R.V. Weiss, T.S. Rickert, and W.T. Linde-Zwirble Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy Cancer 103 2005 1916 1924
7. G.H. Lyman Risks and consequences of chemotherapy-induced neutropenia Clin Cornerstone 8 Suppl. 5 2006 S12 S18
8. J. Crawford, J. Allen, J. Armitage, D.W. Blayney, S.R. Cataland, and M.L. Heaney Myeloid growth factors J Natl Compr Canc Netw 9 2011 914 932
9. D. Abeliovich, L. Kaduri, I. Lerer, N. Weinberg, G. Amir, and M. Sagi The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women Am J Hum Genet 60 1997 505 514
10. J. Crawford, B. Althaus, J. Armitage, L. Balducci, C. Bennett, and D.W. Blayney Myeloid growth factors. Clinical practice guidelines in oncology J Natl Compr Canc Netw 5 2007 188 202
11. T.J. Smith, J. Khatcheressian, G.H. Lyman, H. Ozer, J.O. Armitage, and L. Balducci 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 2006 3187 3205
12. M.S. Aapro, J. Bohlius, D.A. Cameron, L. Dal Lago, J.P. Donnelly, and N. Kearney 2010 update of EORTYC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 2011 8 32
13. G.H. Lyman, and J.M. Kleiner Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy Cancer Treat Res 157 2011 145 165
14. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, and S. Costa A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
15. N.T. Phippen, W.J. Lowery, J.C. Barnett, L.A. Hall, C. Landt, and C.A. Leath III Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study Gynecol Oncol 123 2011 360 364
16. J. Crawford, D.C. Dale, N.M. Kuderer, E. Culakova, M.S. Poniewierski, and D. Wolff Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice J Natl Compr Canc Netw 6 2008 109 118
17. International Collaborative Ovarian Neoplasm Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 2002 505 515
18. M.A. Bookman, H. Malmstrom, G. Bolis, A. Gordon, A. Lissoni, and J.B. Krebs Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J Clin Oncol 16 1998 3345 3352
19. A. du Bois, A. Belau, U. Wagner, J. Pfisterer, B. Schmalfeldt, and B. Richter A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8) Gynecol Oncol 96 2005 444 451
20. D.D. Gibbs, L. Pyle, M. Allen, M. Vaughan, A. Webb, and S.R. Johnston A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer Br J Cancer 86 2002 1379 1384
21. M. Gore, P. Mainwaring, R. A'Hern, V. MacFarlane, M. Slevin, and P. Harper Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group J Clin Oncol 16 1998 2426 2434
22. J.D. Hainsworth, H.A. Burris III, L.H. Morrissey, M. Thomas, J.B. Erland, and J.A. Butts Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network Cancer J 6 2000 151 156
23. A.P. Kudelka, D. Tresukosol, C.L. Edwards, R.S. Freedman, C. Levenback, and P. Chantarawiroj Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma J Clin Oncol 14 1996 1552 1557
24. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, and L.F. Carson Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007
25. M. Markman, A. Kennedy, K. Webster, G. Peterson, B. Kulp, and J. Belinson Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum J Clin Oncol 19 2001 1901 1905
26. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
27. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group) Semin Oncol 23 1996 40 47
28. J.P. Micha, B.H. Goldstein, M.A. Rettenmaier, J. Mattison, C. Graham, and C.L. Birk Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer Gynecol Oncol 94 2004 719 724
29. J.P. Neijt, S.A. Engelholm, M.K. Tuxen, P.G. Sorensen, M. Hansen, and C. Sessa Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 2000 3084 3092
30. 2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis Semin Oncol 24 1997 S15-36-S15-39
31. R.F. Ozols Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer Semin Oncol 22 1995 1 6
32. E.K. Rowinsky, M.R. Gilbert, W.P. McGuire, D.A. Noe, L.B. Grochow, and A.A. Forastiere Sequences of taxol and cisplatin: a phase I and pharmacologic study J Clin Oncol 9 1991 1692 1703
33. P.A. Vasey, R. Atkinson, R. Coleman, M. Crawford, M. Cruickshank, and P. Eggleton Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 2001 170 178
34. C.F. Verschraegen, T. Sittisomwong, A.P. Kudelka, E. Guedes, M. Steger, and T. Nelson-Taylor Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma J Clin Oncol 18 2000 2733 2739
35. A. Jakobsen, K. Bertelsen, J.E. Andersen, H. Havsteen, P. Jakobsen, and K.A. Moeller Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study J Clin Oncol 15 1997 193 198
36. S.B. Kaye, J. Paul, J. Cassidy, C.R. Lewis, I.D. Duncan, and H.K. Gordon Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group J Clin Oncol 14 1996 2113 2119
37. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
38. A.H. Calvert, D.R. Newell, L.A. Gumbrell, S. O'Reilly, M. Burnell, and F.E. Boxall Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756
39. L.C. Harlan, L.X. Clegg, and E.L. Trimble Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States J Clin Oncol 21 2003 3488 3494
40. J.H. Farley, C. Tian, G.S. Rose, C.L. Brown, M. Birrer, and G.L. Maxwell Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials Cancer 115 2009 4210 4217
41. G.H. Lyman, and N.M. Kuderer Epidemiology of febrile neutropenia Support Cancer Ther 1 2003 23 35